CtDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: The ASSESS study

Journal of Thoracic Oncology

Volumn 11, Issue 10, 2016, Pages 1682-1689

  Reck, Martin ^a   Hagiwara, Koichi ^b   Han, Baohui ^c   Tjulandin, Sergei ^d   Grohé, Christian ^e   Yokoi, Takashi ^f   Morabito, Alessandro ^g   Novello, Silvia ^h   Arriola, Edurne ⁱ   Molinier, Olivier ^j   McCormack, Rose ^k   Ratcliffe, Marianne ^k   Normanno, Nicola ^g  

^a Lung Clinic Grosshansdorf   (Germany)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^e Evangelic Lung Clinic Berlin   (Germany)

^f KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h UNIVERSITY OF TURIN   (Italy)

ⁱ Department of Pathology   (Spain)

^j Le Mans General Hospital   (France)

^k ASTRAZENECA   (United Kingdom)

more..

Author keywords

CtDNA; EGFR mutation; NSCLC; Plasma; Realworld

Indexed keywords

CIRCULATING FREE TUMOR DERIVED DNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; AGED; ARTICLE; CYTOLOGY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DNA EXTRACTION; EUROPEAN; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUTATION RATE; NON SMALL CELL LUNG CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; EUROPE; GENETICS; JAPAN; LUNG TUMOR; MUTATION; PATHOLOGY; TREATMENT OUTCOME;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; EUROPE; FEMALE; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84991067898     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.05.036     Document Type: Article

References (25)

1. National Cancer Institute. SEER cancer statistics review, 1975-2012. http://seer.cancer.gov/csr/1975-2012/. Accessed July 8, 2016.
2. Dearden S, Stevens J, Wu YL, et al. Mutation incidence and coincidence in non-small-cell lung cancer: metaanalyses by ethnicity and histology (mutMap). Ann Oncol. 2013;24:2371-2376.
3. Riely GJ, Politi KA, Miller VA, et al. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res. 2006;12:7232-7241.
4. Douillard JY, Ostoros G, Cobo M, et al. Gefitinib treatment in EGFR mutated Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014;9: 1345-1353.
5. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121-128.
6. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957.
7. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239-246.
8. Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, openlabel, randomised, phase 3 study. Lancet Oncol. 2011;12:735-742.
9. National Comprehensive Cancer Network. Practice guidelines in oncology-version V.3.2012 (non-small-cell lung cancer). http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp. Accessed May 19, 2016.
10. NICE. EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer. http://www.nice.org.uk/guidance/dg9. Accessed July 8, 2016.
11. Marchetti A, Normanno N. Recommendations for mutational analysis of EGFR in lung carcinoma. Pathologica. 2010;102:119-126.
12. Pirker R, Herth FJ, Kerr KM, et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol. 2010;5: 1706-1713.
13. Fenizia F, De Luca A, Pasquale R, et al. EGFR mutations in lung cancer: from tissue testing to liquid biopsy. Future Oncol. 2015;11:1611-1623.
14. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958-967.
15. Douillard J-Y, Ostoros G, Cobo M, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer. 2014;110:55-62.
16. AstraZeneca UK Ltd. IRESSA Summary of Product Characteristics. Available at: http://www.medicines.org.uk/ emc/medicine/22104/SPC/. Accessed January 21, 2016.
17. Brambilla E, Travis WD, Colby TV, et al. The new World Health Organization classification of lung tumours. Eur Respir J. 2001;18:1059-1068.
18. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32:579-586.
19. Deans ZC, Bilbe N, O'Sullivan B, et al. Improvement in the quality of molecular analysis of EGFR in nonsmall-cell lung cancer detected by three rounds of external quality assessment. J Clin Pathol. 2013;66: 319-325.
20. Patton S, Normanno N, Blackhall F, et al. Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing. Br J Cancer. 2014;111:413-420.
21. Qiu M, Wang J, Xu Y, et al. Circulating tumor DNA is effective for the detection of EGFR mutation in nonsmall cell lung cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2015;24:206-212.
22. Luo J, Shen L, Zheng D. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Sci Rep. 2014;4:6269.
23. Mok T, Wu YL, Lee JS, et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res. 2015;21: 3196-3203.
24. Karachaliou N, Mayo-de las CC, Queralt C, et al. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial. JAMA Oncol. 2015;1:149-157.
25. Zhao X, Han RB, Zhao J, et al. Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients. Respiration. 2013;85:119-125.